The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Protalix BioTherapeutics Inc shares valued at $205,884 were purchased by Schwartz Aharon on Jun 10 ’25. At $1.60 per share, Schwartz Aharon acquired 129,000 shares. The insider’s holdings grew to 303,000 shares worth approximately $0.72 million following the completion of this transaction.
As published in a research note from H.C. Wainwright on June 08, 2020, Protalix BioTherapeutics Inc [PLX] has been retained to a Buy and the price target has been revised to $11. Analysts at Rodman & Renshaw resumed the stock at ‘”a Buy”‘ outlook in a report released in mid April. As of April 04, 2016, Rodman & Renshaw has initiated its “Buy” rating for PLX. Earlier on April 23, 2015, Jefferies upgraded its rating. Their new recommendation was “a Buy” for PLX stock which previously was a “a Hold”.
Analyzing PLX Stock Performance
On last trading session, Protalix BioTherapeutics Inc [AMEX: PLX] rose 6.31% to $2.36. The stock’s lowest price that day was $2.22, but it reached a high of $2.36 in the same session. During the last five days, there has been a surge of approximately 14.56%. Over the course of the year, Protalix BioTherapeutics Inc shares have jumped approximately 124.76%. Shares of the company reached a 52-week high of $3.10 on 05/01/25 and a 52-week low of $1.32 on 06/23/25.
Support And Resistance Levels for Protalix BioTherapeutics Inc (PLX)
According to the 24-hour chart, there is a support level at 2.27, which, if violated, would cause prices to drop to 2.17. In the upper region, resistance lies at 2.41. The next price resistance is at 2.45. RSI (Relative Strength Index) is 77.96 on the 14-day chart, showing overbought technical sentiment.
Is Protalix BioTherapeutics Inc subject to short interest?
Stocks of Protalix BioTherapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -0.1 million shares to 3.66 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 3.76 million shares. A decline of -2.74% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.19 of the overall float, the days-to-cover ratio (short ratio) decline to 5.19.
Which companies own the most shares of Protalix BioTherapeutics Inc (PLX)?
On November 12, 2014, R. F. Lafferty assigned a price target of “a Buy” to the stock and reiterated coverage with a $5.
